A blog about chemistry, drug development, science, and technology
Amgen is the latest to get into the merger mania and has offerd $420 million for Ilypsa.
Amgen to pay $420 mln cash for Ilypsa - MarketWatch
Amgen wants access to Ilypsa’a ILY101 a drug for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on hemodialysis.
Here is the press release.
Technorati Tags: Amgen, hyperphosphatemia, ILY101, Ilypsa
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 0.962 seconds